Tomographic Parameters of Recurrent Macular Edema Due to Retinal Vein Occlusion during Antiangiogenic Therapy
https://doi.org/10.18008/1816-5095-2021-3S-727-734
Abstract
Purpose: to establish the tomographic parameters to predict the recurrent of macular edema due to retinal vein occlusion.
Patients and methods. This is a retrospective study of 54 patients (54 eyes) with macular edema, no more than 3 months old, who had recurrent of macular edema after 3 intravitreal injections of aflibercept. Standard ophthalmological examination, spectral optical coherence tomography, intravitreal injections of aflibercept according to instruction, and statistical analysis of the data were conducted.
Results. Recurrence of macular edema developed on average 6.3 ± 1.2 weeks after three injections of aflibercept. We identified of the most significant prognostic tomographic parameters affecting the recurrent of macular edema during intravitreal injections of aflibercept — central foveal thickness > 500 μm (OR 2.1, p = 0.01), the presence of serous retinal detachment (OR 5.1, p = 0.001), the presence of hyperreflective foci (OR 3.7, p = 0.03), alteration of external limiting membrane (OR 4.7, p = 0.01), disruption of the photoreceptor innersegment/outer segment junction (OR 3.4, p = 0.01), disruption of retinal pigment epithelium (OR 2.1, p = 0.02).
Conclusion: the recurrent of macular edema with retinal vein occlusion during antiangiogenic therapy depends on baseline tomographic parameters. Our results can be important in predicting the duration and effectiveness of antiangiogenic therapy in a particular patient at the beginning of the disease, which makes the approach to management more personalized, promising in economic, social and psychological aspects.
About the Authors
D. Yu. Khokhlova
State Clinical Hospital № 11
Russian Federation
Russian Federation
Khokhlova Daria Yu., PhD, ophthalmologist
Dzerzhinsky str., 17A, Chelyabinsk, 454129
I. A. Loskutov
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Loskutov Igor A., MD, senior research officer
Rossolimo str., 11A, B, Moscow, 119021
References
1. Hayreh S.S. Retinal vein occlusion. Indian J. Ophthalmol. 1994;42(3):109–132.
2. Scholl S., Augustin А., Loewenstein A. General pathophysiology of macular edema. Eur. J. Ophthalmol.2011;21;10–19. DOI: 10.5301/EJO.2010.6050
3. McIntosh R.L., Rogers S.L., Lim L. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113–1123. DOI: 10.1016/j.ophtha.2010.01.060
4. Boyer D., Heier J., Brown D.M, Clark W.L., Vitti R. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–1032. DOI: 10.1016/j.ophtha.2012.01.042. 1
5. Brown D.M, Heier J.S, Lloyd Clark W., Boyer D.S., Vitti R., Berliner A.J. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013;155(3):429–437. DOI: 10.1016/j.ajo.2012.09.026
6. Holz F.G, Roider J., Ogura Y., Korobelnik J-F, Simader C., Groetzbach G., Vitti R., Berliner J., Hiemeyer F., Beckmann K., Zeitz O., Sandbrink R. VEGF trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. British Journal of Ophthalmology. 2013;97(3):278–284. DOI: 10.1136/bjophthalmol-2012-301504
7. Korobelnik J., Holz F.G., Roider J., Ogura Y. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014;121(1):202–208. DOI: 10.1016/j.ophtha.2013.08.012
8. Choi K.E, Yun C., Cha J., Kim S.W. OCT angiography features associated with macular edema recurrence after intravitreal bevacizumab treatment in branch retinal vein occlusion. Sci Rep. 2019;9(1):14153. DOI: 10.1038/s41598-019-50637-8
9. Jang J.H, Kim Y.C, Shin J.P. Correlation between macular edema recurrence and macular capillary network destruction in branch retinal vein occlusion. BMC Ophthalmol. 2020;20(1):341. DOI: 10.1186/s12886-020-01611-w
10. Aghdam A.K., Reznicek L, Sanjari S.M., Klingenstein A., Kernt M., Seidensticker F. Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion. Clin Ophthalmol. 2017;11:331–336. DOI: 10.2147/OPTH.
11. Forooghian F., Kertes P.J, Eng K.T, Albiani D.A, Kirker A.W, Merkur A.B, Fallah N., Cao S., Cui J., Or C., Matsubara J.A. Alterations in intraocular cytokine levels following intravitreal ranibizumab. Can J Ophthalmol. 2016;51(2):87–90. DOI: 10.1016/j.jcjo.2015.11.001
12. Noma H., Yasuda K., Shimura M. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema. Eur J Ophthalmol. 2021 Jan;31(1):204–210. DOI: 10.1177/1120672119885054
13. Fujihara-Mino A., Mitamura Y., Inomoto N., Sano H., Akaiwa K., Semba K. Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion. Clin Ophthalmol. 2016;10:1305–1313. DOI: 10.2147/
14. Groneberg T., Trattnig J.S., Feucht N., Lohmann C.P., Maier M. Morphologic patterns on spectral-domain optical coherence tomography (SD-OCT) as a prognostic indicator in treatment of macular edema due to retinal vein occlusion. Klin Monbl Augenheilkd. 2016;233(9):1056–1062. DOI: 10.1055/s-0041-108680
15. Mimouni M., Segev О., Dori D. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion. Am. J. Ophthalmol. 2017;182:160–167.
16. Shpak A.A. New nomenclature of optical coherence tomography. Fyodorov Journal of Ophthalmic Surgery = Oftal’mokhirurgiya. 2015;3:80–82 (In Russ.).
17. Budzinskaya M.V., Mazurina N.K., Egorov A.E., Kuroedov A.V., Loskutov I.A., Plyuhova A.A., Razik S., Ryabceva A.A., Simonova S.V. Algorithm for the management of patients with retinal venous occlusions. Message 2. Macular edema. Annals of Ophthalmology = Vestnik oftal’mologii. 2015;131(6):57–66 (In Russ.). DOI: 10.17116/oftalma2015131657-66
18. Erichev V.P., Kozlova I.V., Kosova D.V., Avetisov K.S., Mazurova Yu.V. Dynamics of the macular zone morphometric parameters in patients with glaucoma after phacoemulsification. Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(5-2):129–134 (In Russ.). DOI: 10.17116/oftalma2019135052129
19. Budzinskaya M.V., Fursova A.Zh., Pedanova E.K. Specific biomarkers of response to antiangiogenic therapy. Annals of Ophthalmology = Vestnik oftal’mologii. 2020;136(2):117–124 (In Russ.). DOI: 10.17116/oftalma2020136021117
20. Jung S.H., Kim K.A., Sohn S.W., Yang S.J. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2014 Apr 9;55(4):2290–2296. DOI: 10.1167/iovs.13-13587
21. Drozdova E.A., Hohlova D.Yu. Dynamic assessment of morphological and immunological parameters in macular edema against the background of retinal vein occlusion. Practical medicine = Prakticheskaya meditsina. 2017;3(104):25–29 (In Russ.).
22. Ogino K., Murakami T., Tsujikawa A., Miyamoto K., Sakamoto A., Ota M., Yoshimura N. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012 Jan;32(1):77–85. DOI: 10.1097/IAE.0b013e318217ffc7
23. Do J.R., Park S.J., Shin J.P., Park D.H. Assessment of hyperreflective foci after bevacizumab or dexamethasone treatment according to duration of macular edema in patients with branch retinal vein occlusion. Retina. 2021 Feb 1;41(2):355–365. DOI: 10.1097/IAE.0000000000002826. PMID: 32349101
24. Dogan E., Sever O., Köklü Çakır B., Celik E. Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion. Clin Ophthalmol. 2018;17(12):1465–1470. DOI: 10.2147/OPTH.S162019
25. Celık E., Doğan E., Turkoglu E.B., Çakır B., Alagoz G. Serous retinal detachment in patients with macular edema secondary to branch retinal vein occlusion. Arq Bras Oftalmol. 2016;79(1):9–11. DOI: 10.5935/0004-2749.20160004
26. Khokhlova D.Yu., Drozdova E.A.. Kurysheva N.I., Loskutov I.A. Optical coherence tomographic patterns in patients with retinal vein occlusion and macular edema treated by ranibizumab: a predictive and personalized approach. EPMA J. 2021 Mar 3;12(1):57–66. DOI: 10.1007/s13167-021-00233-6
27. Drozdova E.A., Hohlova D.Yu., Mezenceva E.A., Nikushkina K.V. Investigation of the systemic and local cytokines level in retinal vein occlusion against the background of antiangiogenic therapy. Medical immunology (Russia) = Medicinskaya immunologiya. 2018;20(3):365–372 (In Russ.). DOI: 10.15789/1563-06252018-3-365-372
Review
For citations:
Khokhlova D.Yu., Loskutov I.A. Tomographic Parameters of Recurrent Macular Edema Due to Retinal Vein Occlusion during Antiangiogenic Therapy. Ophthalmology in Russia. 2021;18(3S):727-734. (In Russ.) https://doi.org/10.18008/1816-5095-2021-3S-727-734
Views:
444
Email this article 